Update on stem cell technologies in congenital heart disease
- 9 November 2019
- journal article
- review article
- Published by Wiley in Journal of Cardiac Surgery
- Vol. 35 (1) , 174-179
Abstract
Background Congenital heart disease (CHD) continues to be among the most common birth defects, affecting an estimated 40 000 births annually in the United States. The most common complication of CHD is heart failure. With improved medical management and surgical outcomes, survival for complex congenital heart defects has dramatically improved, but consequentially there are more adults with CHD than children with CHD. Due to longer‐term sequelae of CHD, surgical and medical treatment previously thought to be curative is now realized at best to be palliative, and there is a considerable burden of CHD‐related heart failure. Stem cell therapy as an adjunct to current surgical and medical strategies is being explored in an effort to ameliorate CHD‐related heart failure. This review aims to explore the current literature with regard to stem cell therapy for CHD as well as ongoing trials. Methods A MEDLINE (Ovid), MEDLINE (Pubmed), and clinicaltrials.gov search were performed using the medical subject headings congenital heart defects combined with hematopoietic stem cells, stem cell transplantation, mesenchymal stem cells (MSC), cell‐ or tissue‐based therapy, or MSC transplantation. Articles must have been published after 2010. Results Twenty three articles and 9 ongoing trials met all inclusion criteria. Conclusions Areas of interest include myocardiocyte regeneration, tissue graft development to minimize reoperations, and methods of stem cell delivery. While several small trials are showing promise, it is too soon to make definitive statements about the future of stem cell therapies in this field.Keywords
This publication has 23 references indexed in Scilit:
- Human Neonatal Thymus Mesenchymal Stem/Stromal Cells and Chronic Right Ventricle Pressure OverloadBioengineering, 2019
- Human Neonatal Thymus Mesenchymal Stem Cells Promote Neovascularization and Cardiac RegenerationStem Cells International, 2018
- Cardiac regenerative capacity is age- and disease-dependent in childhood heart diseasePLOS ONE, 2018
- Study design and rationale for ELPIS: A phase I/IIb randomized pilot study of allogeneic human mesenchymal stem cell injection in patients with hypoplastic left heart syndromeAmerican Heart Journal, 2017
- Mesenchymal stem cells preserve neonatal right ventricular function in a porcine model of pressure overloadAmerican Journal of Physiology-Heart and Circulatory Physiology, 2016
- Age-Dependent Effect of Pediatric Cardiac Progenitor Cells After Juvenile Heart FailureStem Cells Translational Medicine, 2016
- Regenerative therapy for hypoplastic left heart syndrome: First report of intraoperative intramyocardial injection of autologous umbilical-cord blood–derived cellsThe Journal of Thoracic and Cardiovascular Surgery, 2015
- A Strong Regenerative Ability of Cardiac Stem Cells Derived From Neonatal HeartsCirculation, 2012
- Human stem cell research and regenerative medicine--present and futureBritish Medical Bulletin, 2011
- Incidence and Risk Distribution of Heart Failure in Adolescents and Adults With Congenital Heart Disease After Cardiac SurgeryThe American Journal of Cardiology, 2006